Market Place
Sourcing Support
FDA Grants Breakthrough Status to Sac-TMT for EGFR NSCLC
03 Dec 2024 //
BUSINESSWIRE
Kelun-Biotech`s TROP2 ADC Approved in China for Advanced TNBC
27 Nov 2024 //
PR NEWSWIRE
Gilead`s CAR-T sales stagnate as Trodelvy takes another write-off
11 Nov 2024 //
FIERCE PHARMA
Gilead withdraws bladder cancer drug in US after failed trial
19 Oct 2024 //
REUTERS
Kelun-Biotech Releases Three SKB264 Study Abstracts At ESMO 2024
09 Sep 2024 //
PR NEWSWIRE
Gilead to Present New Trodelvy® Data at IASLC 2024 World Lung Cancer Conference
05 Sep 2024 //
BUSINESSWIRE
3 Big Pharma companies, 33 phase 3 trials: The race to supremacy in an ADC field
02 Aug 2024 //
FIERCE PHARMA
IDEAYA Biosciences Initiates Phase 1 Trial for IDE397 and Trodelvy® Combination
25 Jun 2024 //
PR NEWSWIRE
Gilead`s Trodelvy fails bladder cancer trial, modestly extends lung cancer survival
31 May 2024 //
REUTERS
MEDSIR, Debiopharm: Breast Cancer Combination Therapy Exploration
28 May 2024 //
BUSINESSWIRE
Merck, Kelun trumpet Phase 3 breast cancer data for anti-TROP2 ADC
23 May 2024 //
ENDPTS
Gilead writes $2.4B off Trodelvy as CEO underscores focus
27 Apr 2024 //
FIERCE PHARMA
Teva snares up to $150M in Abingworth funding for inhaler program
02 Apr 2024 //
FIERCE PHARMA
Dragonfly Announces Collaboration Exploring Combinations of DF1001 with Trodelvy
15 Feb 2024 //
PR NEWSWIRE
Gilead`s Trodelvy fails to meet main goal in lung cancer trial
23 Jan 2024 //
REUTERS
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data
30 Nov 2023 //
PRESS RELEASE
Sacituzumab Govitecan Shows Early Promise in Metastatic Urothelial Carcinoma
31 Oct 2023 //
ONCLIVE
Gilead’s Phase 2 Study of Trodelvy With KEYTRUDA Shows Activity in NSCLC
10 Sep 2023 //
BUSINESSWIRE
EC Approves Gilead’s Trodelvy For Pre-Treated HR+/HER2- Metastatic Breast Cancer
27 Jul 2023 //
BUSINESSWIRE
Gilead`s Trodelvy gets CHMP recommendation for further breast cancer indication
24 Jun 2023 //
PRESS RELEASE
Sacituzumab Govitecan Approaches EU Approval for Pretreated HR+
23 Jun 2023 //
ONCOLIVE
Trodelvy Continues Overall Survival Advantage in Metastatic Breast Cancer
05 Jun 2023 //
BUSINESSWIRE
Gilead picks up small PARP1 biotech to find a mate for Trodelvy
09 May 2023 //
FIERCE BIOTECH
Dutch Ministry Of Health Will Not Reimburse Gilead’s Breast Drug, Trodelvy
01 May 2023 //
FORBES
Gilead posts big gains for cell therapies and Trodelvy
28 Apr 2023 //
FIERCE PHARMA
Pyramid deviates from TRK with deal for rival to Gilead ADC
14 Apr 2023 //
FIERCE BIOTECH
Everest Receives Upfront Payment from Gilead for Trodelvy-Related Transaction
26 Mar 2023 //
PR NEWSWIRE
Gilead says Trodelvy produced durable responses in PII bladder cancer trial
18 Feb 2023 //
NASDAQ
Trodelvy Shows Efficacy Treating Both Platinum-Ineligible & Rapidly Progressing
17 Feb 2023 //
BUSINESSWIRE
VMLY&R, Gilead use AI to turn patient testimonies into paintings
16 Feb 2023 //
FIERCE PHARMA
Gilead`s breast cancer drug gets U.S. FDA approval for third indication
04 Feb 2023 //
REUTERS
Gilead Sciences to provide Trodelvy for Strata PATH trial
19 Jan 2023 //
CLINICAL TRIALS ARENA
EMA Validates Marketing Authorization Application For Trodelvy®
03 Jan 2023 //
BUSINESSWIRE
Data for Trodelvy Demonstrate Efficacy Across Expression Levels in HR+/HER2
06 Dec 2022 //
BUSINESSWIRE
Gilead`s Trodelvy up for FDA breast cancer verdict in February
12 Oct 2022 //
FIERCEPHARMA
Genentech`s Biologic Enspryng (Satralizumab) Receives Approval in the U.S.
14 Sep 2022 //
FDA
Gilead`s Trodelvy extends breast cancer survival by 3.2 months -study
08 Sep 2022 //
REUTERS
Trodelvy Significantly Improved Overall Survival in Pre-Treated HR+/HER2
07 Sep 2022 //
BUSINESSWIRE
New TROPiCS-02 Data in HR+/HER2-Free Survival Benefit of Trodelvy
04 Sep 2022 //
BUSINESSWIRE
Gilead`s Trodelvy chalks up surprise breast cancer survival win
16 Aug 2022 //
FIERCEPHARMA
Gilead to Acquire Remaining Worldwide Rights of Trodelvy
15 Aug 2022 //
BUSINESSWIRE
Arcus Biosciences Reports Second Quarter 2022 Financial Results
03 Aug 2022 //
BUSINESSWIRE
Gilead Sciences’ push into oncology is paying off, as Veklury falters
03 Aug 2022 //
PHARMAPHORUM
AZ`s Enhertu could up the pressure on Gilead`s Trodelvy: experts
13 Jul 2022 //
FIERCEPHARMA
ASCO: Gilead`s below-par Trodelvy breast cancer data cast doubt
06 Jun 2022 //
FIERCEPHARMA
Immunomedics`s Trodelvy (Sacituzumab Govitecan) Receives Approval the U.S.
03 Jun 2022 //
FDA
Genentech to Present Data Across Neuroscience Portfolio at 2022 AAN
24 Mar 2022 //
BUSINESSWIRE
Gilead Sciences will lay off 114 staffers in NJ
10 Mar 2022 //
FIERCEPHARMA
SMC approval welcome news for breast cancer patients
09 Mar 2022 //
PHARMATIMES
Gilead Says Trodelvy Slows Progression of Common Forms of Breast Cancer
08 Mar 2022 //
BIOSPACE
Everest Medicines Announces First Drug Approval of Trodelvy for mTNBC
07 Feb 2022 //
PRNEWSWIRE
New Drug Application for Metastatic Triple-Negative Breast Cancer
04 Jan 2022 //
ETURBONEWS
MFDS Accepts Everest Medicines` NDA for Sacituzumab Govitecan in TNBC
14 Dec 2021 //
PRNEWSWIRE
Trodelvy Demonstrates Clinical Benefit for Black Patients Consistent with TNBC
10 Dec 2021 //
BUSINESSWIRE
Gilead`s Trodelvy (sacituzumab govitecan) gets Approval in Europe
24 Nov 2021 //
EMA
Trodelvy Granted MAA by EC for Metastatic TNBC in Second Line
23 Nov 2021 //
BUSINESSWIRE
Everest Medicines &Gilead Jointly Announce Ph2b Study of Sacituzumab Govitecan
10 Nov 2021 //
PRNEWSWIRE
Gilead and MSD collab on Trodelvy/Keytruda breast cancer trial
28 Oct 2021 //
PHARMATIMES
Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy®
28 Oct 2021 //
PRESS RELEASE
